الفهرس 
Chapter (1): Attention Deficit Hyperactivity Disorder:Only 14 pages are availabe for public view
 |  | from | 110 |  |  |
| | | from | 110 | | |
Abstract
Attention deficit hyperactivity disorder (ADHD) is the most commonly diagnosed neurodevelopmental disorder that begins during early childhood and usually lasts to adulthood. Attention deficit hyperactivity disorder (ADHD) characterized by symptoms of inattention, impulsive behavior, and hyperactivity. It is one of the most commonly diagnosed and treated psychiatric disorders in childhood.
We aimed from this study to screen ADHD child recruited from outpatient psychiatric clinic to detect the prevalence of ADHD subtypes in Egypt, to detect evidence-based treatment in ADHD child managed by pharmacotherapy and to detect neurobiological basis in ADHD children.
This is across sectional-case control study was done on 2 groups: group 1: Contains 30 ADHD children, which divided into 2 equal subgroups, the first subgroup, will receive atomoxetine drug at a dose of (0.5:1.2 mg/kg/day) only. The second sub group will receive methylphenidate drug at a dose not exceeding (18 mg/day).
group 2: control sample was selected from normal children who were matched for age and sex to the children selected for the clinical sample recruited from kafr-Elsheik and Menoufia neuropsychiatric clinics.
Cases were subjected to:
1. Written informed consent obtained from the parent after orienting them to the whole procedure.
2. Demographic data of the child including age, sex and total IQ score by Stanford-bineat.
3. Ksads-pl screening Scale.
4. Ksads-pl diagnostic Scale.
5. Diagnostic interview using MINI-kid for establishment of diagnosis and co morbid condition.
6. EEG before and after treatment.
7. Pharmacotherapy through atomoxetine methylphenidate drug.